Medifast Announces Fourth Quarter and Full Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Medifast (MED) PT Lowered to $16.50 at DA Davidson
February 19, 2025 1:01 PM ESTDA Davidson analyst Linda Bolton Weiser lowered the price target on Medifast (NYSE: MED) to $16.50 (from $17.00) while maintaining a Neutral rating.
The analyst comments "NEUTRAL-rated MED reported a 4Q24 beat. In December, it launched the Ascend line for people who were... More
Medifast (MED) Tops Q4 EPS by 24c, Misses on Revenue; Offers Q1 Revenue Guidance
February 18, 2025 4:10 PM ESTMedifast (NYSE: MED) reported Q4 EPS of $0.10, $0.24 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $119 million versus the consensus estimate of $131.65 million.
GUIDANCE:
Medifast sees Q1 2025 revenue of $100-120 million, versus the consensus of $130.75... More



